FDA Sets Date for First-in-Class Lung Cancer Therapy.

The article focuses on the U.S. Food and Drug Administration's (FDA) approval of datopotamab deruxtecan (Dato-DXd) for treating non-small cell lung cancer (NSCLC), with an action date set for the fourth quarter of 2024. It reports that, if approved, it would be the first TROP2-directed antibody drug conjugate for NSCLC, a significant development considering lung cancer's high incidence and mortality rates.